Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Sermonix Pharmaceuticals logo — Passion and purpose in women’s oncology

Sermonix Pharmaceuticals

Passion and purpose in women’s oncology

Founded 2014 United States Columbus, United States 8 employees Series A Total: $67.55M Biopharma, Pharmaceutical

General Information

Company Name Sermonix Pharmaceuticals
Founded Year 2014
Location United States Columbus, United States +1
Employees 8
Industries Biopharma, Pharmaceutical
Funding Stage Series A
Social

Get notified when Sermonix Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Sermonix Pharmaceuticals

Sermonix Pharmaceuticals is spearheading innovation in women's oncology with a mission underscored by its slogan, "Passion and purpose in women’s oncology." Founded in 2014 by David Portman, MD, the company is a prominent player in the Biopharma and Pharmaceutical industries, with its headquarters in the United States.

Sermonix's core focus lies in developing targeted therapeutics for ESR1-mutated metastatic breast and gynecological cancers. Their pioneering ELAINE Studies explore lasofoxifene, an investigational oral drug promising critical advancements for patients with ER+/HER2- breast cancer with ESR1 mutations.

The company secured its last substantial funding with a $40.00M Series A investment on 15 November 2021, led by the reputable Perceptive Advisors. This investment underscores the confidence and potential seen by major industry stakeholders in Sermonix's targeted oncology solutions.

Taxonomy: Women's Health, Oncology, ESR1 Mutation, Metastatic Breast Cancer, Gynecological Cancers, Targeted Therapeutics, Endocrine Agent, ER+/HER2- Breast Cancer, Selective Estrogen Receptor Modulator, Vulvovaginal Atrophy, Post-Menopausal Osteoporosis, Pharmaceutical Development, Late-Stage Product Commercialization, Clinical Research, Lasofoxifene

Services & Products

Development of Oncology Pharmaceuticals
Clinical Studies and Trials
Commercialization of Women's Cancer Treatments
Research on ESR1 Mutation

Target Customers

Postmenopausal Women with Breast Cancer Premenopausal Women on Ovarian Suppression Oncologists and Healthcare Professionals Pharmaceutical Partners

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 1
Investor
15 Nov 2021
Series A •••••• 4 •••• •••• 31 Jul 2019
Venture Round •••••• - 11 Jul 2016

Sermonix Pharmaceuticals Alternatives & Competitors

View All Alternatives
Sermonix Pharmaceuticals vs
Probmet Therapeutics
Probmet Therapeutics Denmark

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastat...

Convertible Note
2 employees
Health Care, Health and Wellness
Sermonix Pharmaceuticals vs
HAVAH Therapeutics
HAVAH Therapeutics Australia

Developing prevention and early treatment options for hormonally driven breast cancer and other brea...

Series Unknown
5 employees
Biotechnology, Health Care
Sermonix Pharmaceuticals vs
Marvel Medtech
Marvel Medtech United States

Putting the Preventative in Breast Cancer Treatment

2 employees
Biotechnology, Health Care
View all alternatives

FAQ About Sermonix Pharmaceuticals

Passion and purpose in women’s oncology
Sermonix Pharmaceuticals was founded in 2014.
Sermonix Pharmaceuticals is headquartered in Columbus, United States.
Sermonix Pharmaceuticals operates in the following industries: Biopharma, Pharmaceutical.
Sermonix Pharmaceuticals has approximately 8 employees.
Sermonix Pharmaceuticals has completed 3 funding rounds, raising a total of $67.55M. The latest funding stage is Series A.
Sermonix Pharmaceuticals offers: Development of Oncology Pharmaceuticals, Clinical Studies and Trials, Commercialization of Women's Cancer Treatments, Research on ESR1 Mutation.
Top alternatives and competitors to Sermonix Pharmaceuticals include Probmet Therapeutics, HAVAH Therapeutics, Marvel Medtech, Sopherion Therapeutics, Arvinas. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sermonix Pharmaceuticals and Probmet Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Sermonix Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy